What is considered a very low Human Immunodeficiency Virus (HIV) viral load, and at what level should changes be made to Antiretroviral Therapy (ART) medications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

A very low Human Immunodeficiency Virus (HIV) viral load is considered to be below 50 copies/mL. Changes to Antiretroviral Therapy (ART) medications should be made when the HIV RNA level is above 200 copies/mL on at least two consecutive tests, indicating virologic failure 1.

Key Considerations

  • Viral load monitoring: HIV RNA testing should be performed every 3-4 months to evaluate the continuing effectiveness of therapy 1.
  • Virologic failure: Defined as HIV RNA level above 200 copies/mL on at least two consecutive tests, prompting a change in therapy 1.
  • Therapy initiation: Antiretroviral therapy should be initiated after the first viral load measurement is obtained, especially in patients with advanced HIV disease 1.
  • Resistance testing: Should be performed to guide the selection of a new regimen when a patient is on a failing regimen 1.

ART Regimen Considerations

  • First-line treatment: The current recommended first line of treatment is a NNRTI, such as efavirenz, with a nucleoside backbone like Truvada® (emtricitabine and tenofovir disoproxil fumarate) 1.
  • Regimen changes: Single drug switches are not recommended and should only be done when the patient has achieved and maintained optimal viral suppression (i.e., plasma HIV viral load of < 50 copies/mL) 1.
  • New regimen selection: Should contain at least two and preferably three active drugs for patients to obtain optimal results 1.

From the Research

Definition of Very Low HIV Viral Load

  • A very low HIV viral load is typically considered to be below 50 copies/mL 2
  • Some studies define low-level viremia (LLV) as a viral load between 50 and 999 copies/mL 3, 4, 5
  • Very-low-level viremia (VLLV) is a relatively new concept, defined as a viral load between 20 and 50 copies/mL 2

Management of Low-Level Viremia

  • The goal of antiretroviral therapy (ART) is to maintain a suppressed HIV viral load below limits of assay detection 3
  • Persistent LLV, especially between 50 and 200 copies/mL, is associated with an increased risk of virologic failure 3
  • Changes to ART medications may be considered when viral loads remain in LLV, especially if the patient is experiencing virologic failure 3, 5
  • However, some studies suggest that VLLV does not necessarily predict virologic failure and should not prompt more frequent clinic visits or antiretroviral regimen changes 2

Threshold for Changes to ART Medications

  • The threshold at which LLV becomes predictive of disease progression varies between studies, but evidence suggests that incomplete viral suppression leads to the accumulation of resistance mutations and increased risk of virologic progression 5
  • Some studies suggest that a viral load above 1000 copies/mL is a threshold for considering changes to ART medications 6
  • However, other studies suggest that even lower levels of viremia, such as 50-199 copies/mL, may be associated with an increased risk of virologic failure and may require changes to ART medications 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study.

Journal of the International Association of Providers of AIDS Care, 2017

Research

Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013

Research

Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.